Tenax Therapeutics randomizes 230 patients in pivotal Phase 3 LEVEL study
Tenax Therapeutics (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases, announced a major clinical milestone in its Phase 3 LEVEL trial.

_1357173_640x360_2491416643786-640x360.jpg&w=3840&q=75)
_1357159_640x360_2491411523905-640x360.jpg&w=3840&q=75)

_1357111_640x360_2491407427567-640x360.jpg&w=3840&q=75)

_1357057_640x360_2491417155656-640x360.jpg&w=3840&q=75)
_1357057_640x360_2491401283809-640x360.jpg&w=3840&q=75)


_1357001_640x360_2491389507978-640x360.jpg&w=3840&q=75)
_1356989_640x360_2491394115582-640x360.jpg&w=3840&q=75)